In the setting of acute ischemic stroke, intravenous tissue plasminogen activator (IV-tPA), if given within three hours of symptoms onset, has been proven to reduce the combined endpoint of death and disability after stroke [1, 2]. This evidence concerns the gene PLAT and stroke disorder.